At Least One Cyclic Teriparatide Administration Can Be Helpful to Delay Initial Onset of a New Osteoporotic Vertebral Compression Fracture
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Teriparatide markedly increases bone formation and strength, while reducingthe incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors’country does not cover these expenses. This retrospective cohort study comparedthe therapeutic effects of teriparatide on the initial onset of a new OVCF aftertreatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). Materialsand Methods: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). Results: The group with the teriparatide duration of LT3M showed significantly less development of an initialOVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosissignificantly affected multiple regression analysis results (p<0.05). Survivalanalysis of first new-onset OVCFs demonstrated a significantly better survivalrate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). Conclusion: At least one cyclic teriparatide administration is recommended to provide a protectiveeffect against the initial onset of a new OVCF for up to one year after therapy.
Abstract
Purpose: Teriparatide markedly increases bone formation and strength, while reducingthe incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors’country does not cover these expenses. This retrospective cohort study comparedthe therapeutic effects of teriparatide on the initial onset of a new OVCF aftertreatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). Materialsand Methods: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). Results: The group with the teriparatide duration of LT3M showed significantly less development of an initialOVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosissignificantly affected multiple regression analysis results (p<0.05). Survivalanalysis of first new-onset OVCFs demonstrated a significantly better survivalrate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). Conclusion: At least one cyclic teriparatide administration is recommended to provide a protectiveeffect against the initial onset of a new OVCF for up to one year after therapy.
참고문헌 (35)
- Sambrook P, "Osteoporosis", Lancet, 367, pp.2010~2018 (2006)
- Hall SE, "A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture", Osteoporos Int, 9, pp.508~515 (1999)
- Kanis JA, "A new approach to the development of assessment guidelines for osteoporosis", Osteoporos Int, 13, pp.527~536 (2002)
- Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators", JAMA, 282, pp.637~645 (1999)
- Uihlein AV, "Anabolic therapies for osteoporosis", Endocrinol Metab Clin North Am, 41, pp.507~525 (2012)
- Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
- Tseng YY, "Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty", Osteoporos Int, 23, pp.1613~1622 (2012)
- Neer RM, "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344, pp.1434~1441 (2001)
- Park JH, "Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture", OSTEOPOROSIS INTERNATIONAL, 25(2), pp.613~618 (2014), SPRINGER LONDON LTD
- Finkelstein JS, "Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis", J Clin Endocrinol Metab, 95, pp.1838~1845 (2010)
- Kanis JA, "Development and use of FRAX in osteoporosis", Osteoporos Int, 21(Suppl 2), pp.S407~S413 (2010)
- Binkley N, "Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures", Osteoporos Int, 16, pp.1513~1518 (2005)
- improves both cortical and cancellous bone structure, "J Bone Miner Res", 2003, 1932~1941
- Dempster DW, "Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study", J Bone Miner Res, 16, pp.1846~1853 (2001)
- Nevitt MC, "Reduced risk of back pain following teriparatide treatment: a meta-analysis", Osteoporos Int, 17, pp.273~280 (2006)
- Nevitt MC, "Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis", Osteoporos Int, 17, pp.1630~1637 (2006)
- Ulivieri FM, "Back pain treatment in post-menopausal osteoporosis with vertebral fractures", Aging Clin Exp Res, 19(3 Suppl), pp.21~23 (2007)
- Lindsay R, "Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium", J Bone Miner Res, 22, pp.495~502 (2007)
- Martin TJ, "Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis", Osteoporos Int, 19, pp.1125~1138 (2008)
- Cosman F, "Daily and cyclic parathyroid hormone in women receiving alendronate", N Engl J Med, 353, pp.566~575 (2005)
- Nshimyumukiza L, "An economic evaluation: simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures", J Bone Miner Res, 28, pp.383~394 (2013)
- Wasserfallen JB, "Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective", J Med Econ, 11, pp.499~523 (2008)
- McClung MR, "Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass", Arch Intern Med, 165, pp.1762~1768 (2005)
- with alendronate in postmenopausal women with osteoporosis, "J Clin Endocrinol Metab", 2002, 4528~4535
- Mudano AS, "Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study", Osteoporos Int, 20, pp.819~826 (2009)
- Boger A, "Adjacent vertebral failure after vertebroplasty: a biomechanical study of low-modulus PMMA cement", Eur Spine J, 16, pp.118~125 (2007)
- Buchbinder R, "Vertebroplasty: when randomized placebo-controlled trial results clash with common belief", Spine J, 10, pp.241~243 (2010)
- Buchbinder R, "A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures", N Engl J Med, 361, pp.557~568 (2009)
- Kallmes DF, "A randomized trial of vertebroplasty for osteoporotic spinal fractures", N Engl J Med, 361, pp.569~579 (2009)
- Trout AT, "New fractures after vertebroplasty: adjacent fractures occur significantly sooner", AJNR Am J Neuroradiol, 27, pp.217~223 (2006)
- Voormolen MH, "Prospective clinical follow-up after percutaneous vertebroplasty in patients with painful osteoporotic vertebral compression fractures", J Vasc Interv Radiol, 17, pp.1313~1320 (2006)
- Ravn P, "Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group", J Bone Miner Res, 14, pp.1622~1627 (1999)
- 문은수, "The Incidence of New Vertebral Compression Fractures in Women after Kyphoplasty and Factors Involved", Yonsei Medical Journal, 48(4), pp.645~652 (2007), 연세대학교의과대학
- Zhang Z, "Risk factors for new osteoporotic vertebral compression fractures after vertebroplasty: a systematic review and meta-analysis", J Spinal Disord Tech, 26, pp.E150~E157 (2013)
- Blick SK, "Teriparatide: a review of its use in osteoporosis", Drugs, 68, pp.2709~2737 (2008)